# DTMO Executive Status

Date: **2026-08-15**  
Software baseline: **16.0.0rc12 plus accepted post-RC13/E8 repository enhancements**

## Management summary

DTMO has an accepted repository-controlled engineering baseline, an owner-accepted functional product and a repository-complete E8 vulnerability/CTI capability line. The post-E8 candidate has also been externally deployed and extensively tested by the accountable owner in an approved production-equivalent staging environment.

The repository-side Phase 8.2–8.5 validation and acceptance contracts are now complete. **DTMO is not production ready.** The external Phase 8 evidence package still requires final immutable deployment binding and accountable acceptance, after which Phase 9 independent external assurance and Phase 10 formal production go/no-go remain mandatory.

## Current decision position

| Decision area | Status | Consequence |
|---|---|---|
| Engineering baseline | `PASS` | Repository foundation accepted |
| Functional product | `PASS / OWNER_ACCEPTED` | Canonical console journey accepted |
| E8 product evolution | `PASS / REPOSITORY_COMPLETE` | Vulnerability/CTI capabilities repository-complete |
| External post-E8 staging deployment | `PASS / OWNER_VERIFIED_EXTERNAL_EVIDENCE` | Real staging exists and was owner-tested |
| Phase 8.2–8.4 | `CONTRACT COMPLETE / EXTERNAL ACCEPTANCE REQUIRED` | External evidence must be consolidated against one identity |
| Phase 8.5 | `CONTRACT COMPLETE / EXTERNAL OWNER DECISION REQUIRED` | Phase 8 is not yet formally closed |
| Phase 9 | `NOT COMPLETE` | Independent assurance remains mandatory |
| Phase 10 | `NOT STARTED` | No production authorization exists |
| Production deployment | **NO — not approved** | Formal go/no-go has not occurred |

## Demonstrated product scope

DTMO provides a governed unified console for threat/vulnerability intelligence, source operations, canonical intelligence, provenance, severity/classification, native analytics, Administration/RBAC and Governance. The E8 line adds OpenCVE, Vulnerability-Lookup, MISP, AIL, vulnerability prioritization, vulnerability analytics and explicit vulnerability-management governance evidence mapping.

## Key control boundaries

The platform retains server-side RBAC, least privilege, human/service-account separation, privileged-action safeguards, validated bearer-token trust, provenance/confidence preservation, data minimization, auditable request/correlation context and separate human review/external-share authority.

Technical execution does not grant publication authority. Framework mappings do not imply full compliance, maturity or certification. Repository CI does not equal external staging acceptance or independent assurance.

## Remaining release work

### Phase 8 — accountable staging closure

Complete the external evidence package against one immutable post-E8 staging identity. The package must bind exact deployed release/commit, image digests, runtime/configuration evidence and the accepted results for platform/identity, source-to-intelligence and operations/recovery validation. Record approved deviations/residual risks and an explicit accountable Phase 8.5 decision.

### Phase 9 — independent external assurance

After Phase 8 acceptance, execute the agreed independent assurance scope, including penetration testing, hardening/configuration, IAM/secrets, load/stress, resilience/recovery, monitoring/incident-response and relevant privacy/legal/governance review. Release-blocking findings require remediation and retest or accountable formal disposition.

### Phase 10 — production decision

Production may be authorized only after accepted Phase 8 and Phase 9 evidence and formal approval of the production environment, ownership/support, IAM/secrets/network, recovery/rollback, monitoring/escalation, data/privacy/legal and release/change position.

## Executive recommendation

Prioritize **completion and accountable acceptance of the existing Phase 8 external evidence package**. Do not introduce unnecessary product change into the candidate while evidence is being bound and assessed. After Phase 8 is formally accepted, proceed directly to independent Phase 9 assurance.

Do not authorize production use until Phase 10 records an explicit go decision.
